Biolase (BIOL) Reports Q3 Revenue of $6.5 million

Biolase (NASDAQ: BIOL) reported Q3 EPS of ($0.21), versus ($0.25) reported last year. Revenue for the quarter came in at $6.54 million, versus $8.65 million reported last year.

• Adjusted EBITDA loss for the third quarter of 2020 was $2.5 million, or $0.03 per share, compared with Adjusted EBITDA loss of $2.7 million, or $0.12 per share, for the third quarter of 2019.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Iridium Communications (IRDM) Reports In-Line Q1 EPS; offers outlook
• Nokia slightly down as Q1 profit growth fails to meet consensus; outlook unchanged
• Elevance Health (ELV) hikes 2024 earnings outlook, shares climb